18MM people live with T1D across the globe, yet there are no approved disease modifying therapies. This research report from the JDRF T1D Fund, JDRF International, and Health Advances seeks to answer why this is and more.
The field of endocrinology includes a wide range of disease conditions, from orphan diseases such as Cushing’s disease, to major chronic diseases that are challenging our current health care system, notably diabetes and obesity. Multiple treatment regimens and evolving treatment approaches (e.g. surgeries and cellular therapy) complicate commercialization pathways.
- Cushing’s Syndrome
- Diabetes Type 1
- Diabetes Type 2
- Gestational Diabetes
- Idiopathic Short Stature (ISS)
- Latent Autoimmune Diabetes in Adults (LADA)
- Metabolic Syndrome
- Polycystic Ovary Syndrome
- Testosterone Deficiency
As type 2 diabetes reaches epidemic proportions, it has become one of the most active development and commercial areas across the pharmaceutical, diagnostic and device industries. Companies are facing higher hurdles to succeed in the market due to growing competition, heightened awareness of safety risks, and greater scrutiny from FDA on surrogate markers. Developing successful treatments for obesity, a major comorbidity of diabetes, continues to challenge companies. The lack of a foundational therapy like metformin places unrealistic efficacy goals on new products. Finally, innovation in diabetes complication treatments require stronger knowledge of mechanisms and biomarkers.
View our Diabetes, Obesity, and Endocrine Diseases case examples.